Extracellular signal regulated kinases, ERK1/2 and ERK5, are activated by asbestos fibers in mesothelial? and airway epithelial cells and play critical roles in cell survival. ERK1/2-dependent Fra-1 expression is also? linked causally to morphologic transformation of rat mesothelial cells and expression of genes (c-met, cd44)? stimulating cell proliferation and migration. We hypothesize that activation of ERK1/2 and ERK5 signaling? pathways occur by carcinogenic fibers (asbestos, erionite) in the pathogenesis of human malignant? mesothelioma (MM) and are potentiated by SV40 in a co-carcinogenic manner. Recent exciting data also? suggest that these survival pathways are activated in MMs after exposure to chemotherapeutic drugs and? can be manipulated to achieve increased cell killing. Thus, we also hypothesize that ERK1/2 and ERK5? pathways contribute, alone or cooperatively, to MM cell survival after chemotherapy.
In Aim 1, we will test? crocidolite and chrysotile asbestos, well-characterized Turkish erionite (see Project 1), and their nonfibrous? analogs, alone and with co-exposures to SV40 to determine if ERK1/2, and ERK5 activity, fos/jun family? members, and AP-1 transactivation correlate with patterns of transformation and carcinogenicity as? determined in the in vitro/in vivo models developed by Dr. Carbone (Core C).
In Aim 2, we will use a panel? of SV40+ and - MMs from Core B to determine the effects of dominant negative constructs and small hairpin? (sh) RNA interference (RNAi) vectors targeting ERK1/2 and ERK5 on parameters of in vitro cell? transformation and survival after treatment with Carmustine (BCNU). In collaboration with Dr. Testa (Project? 3) we will also determine if the AKT survival pathway is modified in these studies.
In Aim 3, a mouse? orthotopic model will be used to determine if SV40+ and - MMs stably transfected with shMEKI, shERKS or? both constructs before intrapleural injection and administration of Carmustine, have altered growth and? metastases. Identifying the pathways of cell survival in the pathogenesis of MMs is highly significant for? prevention and treatment of these devastating tumors. This Program Project allows our previous? mechanistic studies in rodent mesothelioma models to be validated in human mesotheliomas and provides? us with expertise on virology and MM pathology (Dr. Carbone), AKT survival pathways (Dr. Testa) and use? of normal human mesothelial and MM cells (Dr. Pass).
|Napolitano, A; Pellegrini, L; Dey, A et al. (2016) Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 35:1996-2002|
|Yang, H; Pellegrini, L; Napolitano, A et al. (2015) Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell Death Dis 6:e1786|
|Nasu, Masaki; Emi, Mitsuru; Pastorino, Sandra et al. (2015) High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 10:565-76|
|Bononi, Angela; Napolitano, Andrea; Pass, Harvey I et al. (2015) Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Rev Respir Med 9:633-54|
|Baumann, Francine; Buck, Brenda J; Metcalf, Rodney V et al. (2015) The Presence of Asbestos in the Natural Environment is Likely Related to Mesothelioma in Young Individuals and Women from Southern Nevada. J Thorac Oncol 10:731-7|
|Baumann, Francine; Flores, Erin; Napolitano, Andrea et al. (2015) Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 36:76-81|
|Baumann, Francine; Buck, Brenda J; Metcalf, Rodney V et al. (2015) Reply to ""No Increased Risk for Mesothelioma in Relation to Natural-Occurring Asbestos in Southern Nevada"". J Thorac Oncol 10:e64-5|
|Deng, Xu-Bin; Xiao, Li; Wu, Yue et al. (2015) Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy. Int J Cancer 137:481-90|
|Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91|
|Menges, Craig W; Kadariya, Yuwaraj; Altomare, Deborah et al. (2014) Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. Cancer Res 74:1261-1271|
Showing the most recent 10 out of 52 publications